当前位置: 首页 > 期刊 > 《中国医学创新》 > 2019年第11期
编号:13382742
关于恶性胸膜间皮瘤的病因和内科治疗的简述(7)
http://www.100md.com 2019年4月15日 《中国医学创新》 2019年第11期
     [38] Khanna S,Thomas A,Abatedaga D,et al.Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab[J].Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer,2016,11(11):1993-2005.

    [39] Assan R,Kindler H L,Jahan T,et al.Phase Ⅱ clinical trial of amatuximab,a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma[J].Clin Cancer Res,2014,20(23):5927-5936.

    [40] Treasure T,Lang-Lazdunski L,Waller D,et al.Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma:clinical outcomes of the mesothelioma and radical surgery(MARS)randomised feasibility study[J].Lancet Oncol,2011,12(8):763-772.

    [41] Van Z N,Clarke C,Henderson D,et al.Guidelines for the diagnosis and treatment of malignant pleural mesothelioma[J].

    J Thorac Dis,2013,5(6):E254-E307.

    [42]何一兵,姜靜波,吴宏成,等.培美曲塞联合顺铂治疗八例恶性胸膜间皮瘤疗效分析[J].中国医师进修杂志,2011,34(29):42-43.

    [43] Rossini M,Rizzo P,Bononi I,et al.New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma[J].Front Oncol,2018,8:91.

    (收稿日期:2019-01-03) (本文编辑:程旭然), 百拇医药(李智昊 呼群)
上一页1 2 3 4 5 6 7